Archive | Publications

Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size

Since largest basal diameter (LBD) seems to have independent prognostic worth in uveal melanoma (UM), this topic is further studied herein among all patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications

Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma

In patients with primary cutaneous melanoma, this study was undertaken to investigate if histologically confirmed regression was correlated with better or worse survival.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release.

Read the full story

Posted in Melanoma News, Regulatory, Publications

The Paradoxical Behavior of microRNA-211 in Melanomas and Other Human Cancers

Cancer initiation, progression, and metastasis leverage many regulatory agents, such as signaling molecules, transcription factors, and regulatory RNA molecules.

Read the full story

Posted in Melanoma News, Regulatory, Publications